Intralesional immunotherapy as a strategy to treat melanoma.

about

Scalping Surgery - Dermatologic Indications beyond Curative Primary Skin Cancer Surgery.

P2860

Q41179537-DFB7E525-5F03-432D-A99D-9CAA661A9B29

P2860

Intralesional immunotherapy as a strategy to treat melanoma.

Item

http://www.wikidata.org/entity/Q38742761

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Intralesional immunotherapy as a strategy to treat melanoma.

@en

type

Item

label

Intralesional immunotherapy as a strategy to treat melanoma.

@en

prefLabel

Intralesional immunotherapy as a strategy to treat melanoma.

@en

P1476

Intralesional immunotherapy as a strategy to treat melanoma.

@en

P2093

Noura Nouri

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma.

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.

The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014

Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.

P304

619-626

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2016.1157161

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Claus Garbe

P577

2016-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26898656

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

Intralesional immunotherapy as a strategy to treat melanoma.

about

P2860

P2860

Intralesional immunotherapy as a strategy to treat melanoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921